Unknown

Dataset Information

0

A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK.


ABSTRACT: The COVID-19 pandemic has created many challenges in the management of immune thrombocytopenic purpura (ITP). The recommendation for avoidance of steroids by WHO led to the off-licence use, supported by NHS England, of thrombopoietin mimetics (TPO-RA) for newly diagnosed or relapsed ITP. This is a real-world prospective study which investigated the treatment patterns and outcomes in this setting. Twenty-four hospitals across the UK submitted 343 cases. Corticosteroids remain the mainstay of ITP treatment, but TPO-RAs were more effective. Incidental COVID-19 infection was identified in a significant number of patients (9·5%), while 14 cases were thought to be secondary to COVID-19 vaccination.

SUBMITTER: Rampotas A 

PROVIDER: S-EPMC8652653 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-BSST1055 | biostudies-other
| S-EPMC7674996 | biostudies-literature
| S-EPMC7276755 | biostudies-literature
| 2346925 | ecrin-mdr-crc
| S-EPMC9245799 | biostudies-literature
| S-EPMC8528316 | biostudies-literature
| S-EPMC8760704 | biostudies-literature
| S-EPMC9021047 | biostudies-literature
| S-EPMC7520144 | biostudies-literature
| S-EPMC7985094 | biostudies-literature